A fixed-dose combination (FDC) of Desvenlafaxine, a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) antidepressant, and Clonazepam, a high-potency benzodiazepine with anxiolytic, anticonvulsant, and muscle relaxant properties. This combination is primarily used for the management of Major Depressive Disorder (MDD) with significant comorbid anxiety or agitation. It aims to provide rapid relief of anxiety symptoms while the antidepressant effect builds over weeks. The FDC is controversial and its approval in India is under scrutiny due to potential for misuse, dependence, and additive CNS depression.
Adult: One tablet (Desvenlafaxine 50mg + Clonazepam 0.5mg) orally once daily, usually in the evening to minimize daytime sedation. May be taken with or without food. The clonazepam component should ideally be used for the shortest duration possible (2-4 weeks).
Note: Swallow whole with water. Do not crush, chew, or break. Avoid abrupt discontinuation; taper gradually under medical supervision to prevent withdrawal symptoms (especially clonazepam) and discontinuation syndrome (desvenlafaxine).
Desvenlafaxine is the major active metabolite of venlafaxine. It potently inhibits the reuptake of serotonin (5-HT) and norepinephrine (NE) at the presynaptic neuron, increasing the concentration of these neurotransmitters in the synaptic cleft. This enhances serotonergic and noradrenergic neurotransmission, which is implicated in mood regulation. Clonazepam potentiates the effect of the inhibitory neurotransmitter GABA by binding to the benzodiazepine site on the GABA-A receptor, increasing the frequency of chloride channel opening, leading to neuronal hyperpolarization and reduced excitability.
Pregnancy: Desvenlafaxine: Category C (US FDA). Limited human data, potential risks. Clonazepam: Category D (US FDA). Associated with fetal malformations (cleft lip/palate), neonatal withdrawal syndrome, and floppy infant syndrome. USE DURING PREGNANCY IS GENERALLY NOT RECOMMENDED, especially in first trimester. Only if potential benefit justifies potential fetal risk.
Driving: PATIENTS SHOULD NOT DRIVE OR OPERATE HEAVY MACHINERY, especially during initial treatment and dose adjustments, due to significant risk of dizziness, drowsiness, and impaired cognitive function.
| Monoamine Oxidase Inhibitors (MAOIs) - Selegiline, Phenelzine | Risk of severe, potentially fatal serotonin syndrome. | Contraindicated |
| Other CNS Depressants - Alcohol, Opioids, Barbiturates, other Benzodiazepines | Additive CNS depression, profound sedation, respiratory depression, risk of death. | Major |
| Strong CYP3A4 Inhibitors - Ketoconazole, Itraconazole, Clarithromycin, Ritonavir | Increased plasma levels of Clonazepam, leading to enhanced effects and toxicity. | Major |
| Anticoagulants/Antiplatelets - Warfarin, Aspirin, NSAIDs | Increased risk of bleeding due to desvenlafaxine's effect on serotonin in platelets. | Moderate |
| Drugs that prolong QT interval - Class IA/III antiarrhythmics, some antipsychotics, antibiotics | Additive risk of QT prolongation and cardiac arrhythmias. | Moderate |
| Serotonergic Drugs - Tramadol, Triptans, Linezolid, other SSRIs/SNRIs | Increased risk of serotonin syndrome. | Moderate |
Same composition (Desvenlafaxine (50mg) + Clonazepam (0.5mg)), different brands: